Clinical Trial Update: SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma [Phase 1]

View source ↗

Summary

Phase 1 trial update for SynKIR-110 in mesothelin-expressing ovarian cancer, cholangiocarcinoma, and mesothelioma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Malignant Mesothelioma
• Ovarian Cancer

Drugs mentioned

• SynKIR-110 (SynKIR-110)

Snippet

Sponsor: Verismo Therapeutics | Conditions: Ovarian Cancer, Cholangiocarcinoma Recurrent | Phase 1 | Status: RECRUITING